Research Article

Apatinib Functioned as Tumor Suppressor of Synovial Sarcoma through Regulating miR-34a-5p/HOXA13 Axis

Qi Feng, Donglai Wang, Peng Guo, Zibo Zhang, and Jiangang Feng

Department of Orthopedics, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011 Hebei Province, China

Correspondence should be addressed to Jiangang Feng; jiangang_feng@zcmu.edu.cn

Received 15 August 2022; Accepted 3 September 2022; Published 12 October 2022

Academic Editor: Liaqat Ali

Copyright © 2022 Qi Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Synovial sarcoma is a rare malignant tumor. The role of apatinib in synovial sarcoma remains unclear. In this study, we aimed to determine the biological functions and the potential molecular mechanism of action of apatinib in synovial sarcoma.

Methods. SW982 cells were stimulated with apatinib. The relative expression of the genes was determined by performing qPCR. Protein levels were evaluated by western blot and immunohistochemistry assays. Proliferation, apoptosis, migration, and invasion of SW982 cells were determined by the CCK-8 assay, clone formation assay, flow cytometry, wound healing, and the transwell assay, respectively. Additionally, SW982 cells were injected into mice to induce synovial sarcoma. Results. Apatinib decreased the proliferation, migration, and invasion but increased the apoptosis of SW982 cells. Apatinib repressed tumor growth in vivo and elevated miR-34a-5p in SW982 cells. The inhibition of miR-34a-5p repressed the reduction of proliferation, migration, and invasion and also the elevation of apoptosis in apatinib-treated SW982 cells. Apatinib repressed tumor growth in vivo and elevated miR-34a-5p in SW982 cells. The inhibition of miR-34a-5p repressed the reduction of proliferation, migration, and invasion and also the elevation of apoptosis in apatinib-treated SW982 cells. The luciferase activity decreased after cotransfection of the miR-34a-5p mimic and the wild-type HOXA13 vector. Additionally, an increase in miR-34a-5p repressed the levels of HOXA13 mRNA and protein. Moreover, HOXA13 reversed these patterns caused by the inhibition of miR-34a-5p in apatinib-treated SW982 cells. Conclusion. Apatinib elevated miR-34a-5p and reduced HOXA13, leading to a significant decrease in proliferation, migration, and invasion, along with an enhancement of apoptosis in SW982 cells. Apatinib suppressed tumorigenesis and tumor growth in SW982 cells in vivo.

1. Introduction

Soft tissue tumors are a group of more than 60 tumors formed by the overproliferation of mesodermal cells and range from benign lipomas to aggressive metastatic angiosarcomas [1]. Among these, sarcoma is a type of malignant tumor that is very aggressive and has a high infiltration ability. There are two broad categories of sarcomas, comprising the synovial sarcoma and the bone sarcoma [2]. There are approximately 4–5 cases of sarcoma in every 100,000 individuals [3]. Unfortunately, there is a marginal effect of cancer treatment on the recurrence and survival of patients with sarcoma due to the lack of effective treatment methods to inhibit tumorigenesis in synovial sarcoma [4]. The advancement in molecular genetics has contributed to the management of synovial sarcoma [5, 6]. The mechanism of tumorigenesis plays a key role in the development of malignant behaviors of sarcomas [7]. A study suggested that treatment based on molecular genetics might contribute to the clinical outcome of advanced sarcoma and indicated that molecular genetics is needed for clinical treatment to elucidate the molecular pathogenesis of synovial sarcoma [8]. Mesylate apatinib, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), has been used for the treatment of various types of cancers due to its antiangiogenic role via competition for the ATP-binding site of VEGFR2 [9]. Yang et al. [10] showed that mesylate apatinib significantly reduced the hyperproliferation and malignant metastasis in epithelioid malignant peritoneal mesothelioma. By performing a randomized trial, a study showed that apatinib significantly improved tumor symptoms and progression-free survival of patients with advanced progressed lung adenocarcinoma [11]. A study suggested that mesylate apatinib combined with recombinant human endostatin can improve non-small-cell lung cancer in the short term and enhance the results in the long term [12]. Apatinib has a
potential role in the clinical treatment of sarcoma. Tian et al. [13] found that the treatment of apatinib improved the progression-free survival and the overall survival substantially and also significantly inhibited the progression to advanced sarcoma. Apatinib can increase autophagy and apoptosis in osteosarcoma by targeting the VEGFR2-mediated signal transducer and activator of transcription 3 (STAT3)/B-cell lymphoma-2 (Bcl-2) pathway [14]. Apatinib reduces the doxorubicin resistance of osteosarcoma via the STAT3-mediated SRY-box transcription factor 2 (Sox2) pathway and represses the programmed cell death 1 ligand 2 (PD-L2) mediated immune escape in osteosarcoma by mediating the VEGFR2 and STAT3/ras homolog family member A (RhoA)/rho-associated coiled-coil containing protein kinase 1 (ROCK1)/LIM domain kinase 2 (LIMK2) pathways [15, 16]. However, the mechanism of action of apatinib in synovial sarcoma is unknown.

MicroRNAs (miRNAs) play an important role in tumorigenesis and tumor growth associated with synovial sarcoma by deregulating cellular proteins or related pathways [17]. Dysregulation of miRNAs acts as the potential biomarkers of synovial sarcoma based on their association with malignant tumors [18]. The miR-34 family, including miR-34a/b/c, a critical tumor regulator and potential therapeutic target in malignant tumor, is downregulated in ovarian cancer, gastric cancer, colon cancer, and sarcoma [19–23]. The miR-34a-5p, a mature form of miR-34a-3a, is associated with the tumorigenesis of sarcoma. Li et al. [24] found that miR-34a-5p functions by reducing the proliferation and elevation of apoptosis in Ewing sarcoma. Scandra et al. [25] suggested that the expression of miR-34a might contribute to the prognosis of synovial sarcoma in the clinic. An increase in the expression of miR-34a improved the outcome of patients with Ewing sarcoma [26]. However, the mechanism of action of miR-34a-5p in synovial sarcoma is unclear.

We found a complementary fragment of miR-34a-5p in the Homeobox A13 (HOXA13) mRNA based on starBase 2.0, which suggested a potential interaction between miR-34a-5p and HOXA13. HOXA13 is located on chromosome 7 and encodes a protein (transcription factor) with DNA-binding activity that modulates gene expression. The deregulated expression of HOXA13 occurs in esophageal squamous cell carcinoma, hepatocellular carcinomas, and gastric cancer [27–29], thus resulting in the development and progression of malignant tumors. The miR-34a-5p can target HOXA13 through miRNA-mRNA interaction in bone sarcoma [30]. However, it is not known whether miR-34a-5p binds to the HOXA13 mRNA to modulate its expression that, in turn, can contribute to tumorigenesis and progression in synovial sarcoma. Also, whether the miR-34a-5p/HOXA13 axis mediates the mechanism of action of apatinib during the progression of synovial sarcoma is unclear.

Based on this information, we hypothesized that mesylate apatinib might upregulate miR-34a-5p and decrease HOXA13 levels, leading to the inhibition of tumorigenesis and the progression of synovial sarcoma. We aimed to elucidate a novel mechanism of action of mesylate apatinib in synovial sarcoma for improving the marginal effect of drug treatment in the clinic.

2. Methods

2.1. Cell Culture and Transfection. Synovial sarcoma cells (SW982) purchased from the American Type Culture Collection (ATCC, USA) were cultured with Dulbecco’s modified Eagle medium (DMEM, Hyclone, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA) at 37°C with 5% CO2 and 95% air. Then, the miR-34a-5p mimic, negative control of miR-34a-5p mimic (NC mimic), miR-34a-5p inhibitor, negative control of miR-34a-5p inhibitor (NC inhibitor), and HOXA13 shRNA were purchased from Sangon Biotech Pvt., Ltd. (China) and transfected into SW982 cells via Lipofectamine 2000 (Invitrogen, USA). The sequences of shRNAs, miRNA mimic, and miRNA inhibitor were listed as follows: sh-HOXA13, 5′-GTT CCA GAA CAG GAG GGT TAA-3′; miR-34a-5p mimic, 5′-UGG CAG UGU CUU AGC UGG UUG U-3′; and miR-34a-5p inhibitor, 5′-ACC GUC ACA GAA UCG ACC A-3′.

2.2. Cell Counting Kit-8 (CCK-8) Assay. The SW982 cells were incubated in 96-well plates supplemented with DMEM and 10% FBS for 48 h. To determine the optimum concentration of apatinib in the SW982 cells, the cells were incubated with 0, 5, 10, 20, and 50 μM apatinib for 48 h. Then, the cell viability was measured by performing the CCK-8 assay (Elabscience, China). Briefly, the SW982 cells were cultured in the CCK-8 solution for 3 h at 37°C with 5% CO2 and 95% air. Then, they were measured using an enzyme-linked immunometric meter at 450 nm. To demonstrate the role of apatinib in cell proliferation, the SW982 cells were incubated with 10 μM apatinib for 48 h, followed by analysis via the CCK-8 assay.

2.3. Clone Formation Assay. Initially, 10 μM apatinib-treated SW982 cells with different transfection treatments were seeded in six-well plates incubated with DMEM containing 10% FBS for 14 d, followed by immobilization with 4% paraformaldehyde for 30 min. Then, the cells were stained using crystal violet dye for 20 min. Finally, clone formation was evaluated from images taken with a microscope (Nikon, Japan).

2.4. Flow Cytometry. After different transfection treatments, 10 μM apatinib-treated SW982 cells at a density of 100,000 cells were incubated with ice-cold 70% ethanol solution, followed by incubation with Annexin V-FITC (Procell, China) and propidium iodide buffer (Procell, China) for 20 min in the dark. The visualization of apoptosis was performed by using a flow cytometry system (BD Biosciences, USA).

2.5. Wound Healing. Briefly, 10 μM apatinib-treated SW982 cells with different transfection treatments were seeded in six-well plates for 24 h at 37°C with 5% CO2 and 95% air. Then, the cells were scraped using a sterile pipette tip. The photographs of the SW982 cells were taken using a microscope (Nikon, Japan) at 0 h and 24 h, respectively.

2.6. Transwell Assay. Initially, 10 μM apatinib-treated SW982 cells with different transfection treatments were seeded in the upper chamber, which was precoated with 8% Matrigel (BD, USA) and supplemented with FBS-free...
DMEM. The bottom chamber was supplemented with DMEM with 20% FBS to induce invasion of the SW982 cells. After incubation for 24 h, the cells in the bottom chamber were counted in five randomly selected fields using a microscope (Nikon, Japan).

2.7. Quantitative Real-Time PCR (qPCR). Total RNA was extracted from 10 μl of apatinib-treated SW982 cells with different transfection treatments using TRIzol reagent and measured using a spectrophotometer at 260 nm and 280 nm. The reverse transcription and quantification of the RNA sample were performed using the TaqMan One-Step RT-qPCR Kit (Solarbio, China) and the ABI7000 Sequence Detection System (Applied Biosystems, USA). The primers of miR-34a-5p and HOXA13 were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). GAPDH and U6 were used as internal controls. The relative expression was calculated by the 2 ΔΔCq method. The miR-34a-5p-forward primer was 5′-AAC GTG CAG CAC TTC TAG GG-3′; the miR-34a-5p-reverse primer was 5′-GGC CAG CTG TGA GTG TTT CT-3′; the HOXA13-forward primer was 5′-TTG GGG GTT GAC TGT TGA CA-3′; the HOXA13-reverse primer was 5′-ACA GGA TTG TAC AGC GGG TG-3′; the U6-forward primer was 5′-CTC GCT TCG GCA GCA CA-3′; the U6-reverse primer was 5′-AAC GCT TCA CGA ATT TGC GT-3′; the GAPDH-forward primer was: 5′-CCA GGT GTT CTC CTC TGA-3′; and the GAPDH-reverse primer was 5′-GCT GTA GCC AAA TCG TTG T-3′.

2.8. Dual-Luciferase Reporter Gene. Based on starBase 2.0 (https://starbase.sysu.edu.cn/starbase2/index.php), a complementary fragment of miR-34a-5p was found in the HOXA13 mRNA. The 3′-UTR sequences of HOXA13 with prediction sites were amplified, which were loaded in the pmirGLO (pmirGLO-HOXA13 wt). The pmirGLO loaded with HOXA13 mutant without prediction site (pmirGLO-HOXA13 mut) was used for the control of pmirGLO-HOXA13 wt. Then, the HEK293 cells purchased from ATCC were seeded and cultured in cell plates, which were transfected pmirGLO-HOXA13 wt, pmirGLO-HOXA13 mut and the miR-34a-5p mimic or the NC mimic using Lipofectamine 2000 (Invitrogen, USA). The luciferase activity was detected through the dual-luciferase reporter assay system (Promega, USA).

2.9. Tumor Xenografts. This study was approved by the hospital ethics committee following the Health Guide of National Institutes for the Care and Use of Laboratory Animals (approval no. MKDN-2021-027). Six-week-old female BALB/c nude mice purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (China) were subcutaneously injected with SW982 cells at a density of 2,000,000 cells. The mice were randomly divided into the dimethyl sulfoxide (DMSO) group or the apatinib group, with 10 mice in each group. Briefly, the mice in the DMSO group were treated with DMSO orally daily for 30 d, while the mice in the apatinib group were orally administered 50 mg/kg apatinib daily for 30 d. The tumor volume was measured every five days. Tumor volume was calculated as tumor volume = width 2 × length/2. On day 30, the tumors were dissected, photographed, and weighed.

2.10. Immunohistochemistry. The tumor tissues from the mice were fixed using a 10% neutral formalin-buffered solution and repaired with Tri-s-EDTA solution, followed by incubation with Tris-buffered saline containing 1% BSA and 10% normal serum at room temperature for 2 h. The tissues were incubated with the VEGFR2 antibody (ab115805, 1:100, Abcam, Cambridge, UK), Ki67 antibody (ab15580, 1:1000, Abcam, Cambridge, UK), cleaved caspase-3 (9661S, 1:400, Cell Signaling, Danvers, Massachusetts, USA), or cleaved caspase-9 (10380–1-AP, 1:50, Proteintech, USA) for 12 h at 4°C, followed by incubation with the secondary antibody (ab150071, 1:500) for 1 h at room temperature.

2.11. Western Blot Assay. Total protein was extracted from the SW982 cells or tumor tissues using RIPA lysis buffer (Beyotime, China), followed by separation using an SDS-PAGE electrophoresis system (Bio-Rad, USA) after the total protein was measured by performing bicinchoninic acid (BCA) assay (Beyotime, China). Then, the protein samples were transferred from the gel onto a polyvinylidene difluoride (PVDF) membrane (Millipore, Germany) and blocked with 5% skimmed milk for 12 h at 4°C, followed by incubation with the HOXA13 antibody (ab172570, 1:1000, Abcam, Cambridge, UK), VEGFR2 antibody (ab221679, 1:1000, Abcam, Cambridge, UK), Ki67 (ab16667, 1:1000, Abcam, Cambridge, UK), cleaved caspase-3 antibody (ab214430, 1:5000, Abcam, Cambridge, UK), and cleaved caspase-9 antibody (ab2324, 1:1000, Abcam, Cambridge, UK) for 12 h at 4°C. The protein blots were visualized using the ECL kit (Thermo Scientific, China) and the Bio-Rad XR gel imaging analysis system (Bio-Rad, USA) after incubation with Goat Anti-Rabbit IgG H&L antibody (1:10000). All antibodies were purchased from Abcam (UK).

2.12. Statistical Analysis. The data were presented as the mean ± standard deviation (SD) and processed using the GraphPad 8.0 software. Data were collected from at least three independent experiments. The differences between any two groups were determined by performing independent sample t-tests. The differences among three or more groups were determined by performing one-way analysis of variance (ANOVA), followed by multiple comparisons by performing the LSD test. The differences between and among groups were considered to be statistically significant at P < 0.05 and 95% confidence interval, based on the two-sided test.

3. Results

3.1. Apatinib Repressed Malignant Behaviors of SW982 Cells. To investigate the effect of apatinib on malignant behaviors, the SW982 cells were stimulated with various concentrations of apatinib for 48 h. The cell viability decreased with an increase in the concentration of apatinib (Figure 1(a)), and
Figure 1: Continued.
10 μM apatinib was selected as the optimal concentration and used in the following study. Similarly, apatinib significantly reduced the proliferation of SW982 cells, determined by the colony formation assay (Figure 1(b)). The results of the flow cytometry assay showed that there was also an increase in the apoptosis of apatinib-treated SW982 cells compared to the level of apoptosis in cells not administered apatinib treatment (Figure 1(c)). Apatinib significantly reduced the migration and invasion of the SW982 cells compared to those activities of the cells in the control group (Figures 1(d) and 1(e)). At the protein level, apatinib decreased the expression of VEGFR2 and Ki67 in SW982 cells and increased the expression of cleaved caspase-3 and cleaved caspase-9 (Figure 1(f)). Moreover, to determine the effect of apatinib on miR-34a-5p, qPCR analysis was performed, and the results showed that the level of miR-34a-5p increased substantially after apatinib treatment compared to the level of miR-34a-5p in the control (Figure 1(g)). This indicated that miR-34a-5p might be the mediator of apatinib in SW982 cells. Overall, apatinib decreased the migration, invasion, proliferation, and elevation of apoptosis in SW982 cells.

3.2. Apatinib Suppressed Malignant Behaviors of SW982 Cells by Upregulating miR-34a-5p. To determine whether apatinib can inhibit SW982 cells via miR-34a-5p, miR-34a-5p was repressed by the miR-34a-5p inhibitor in SW982 cells (Figure 2(a)). The downregulation of miR-34a-5p increased the proliferation of SW982 cells following apatinib treatment (Figures 2(b) and 2(c)). Subsequently, we examined the effect of miR-34a-5p on apatinib-stimulated apoptosis. The results suggested that after treatment with apatinib along with the miR-34a-5p inhibitor, the apoptosis of SW982 cells was considerably reduced (Figure 2(d)). The decrease in miR-34a-5p suppressed the apatinib-induced reduction of migration and invasion of the SW982 cells (Figures 2(e) and 2(f)). The results of the western blot assay showed that the miR-34a-5p inhibitor increased the levels of the VEGFR2 and Ki67 proteins that were reduced by apatinib and suppressed the levels of cleaved caspase-3 and cleaved caspase-9 that were increased by apatinib (Figure 2(g)). These results suggested that apatinib inhibits multiple malignant behaviors of SW982 cells by regulating miR-34a-5p.

3.3. miR-34a-5p Targeted HOXA13 in SW982 Cells. To determine the function of miR-34a-5p in apatinib-inhibited malignant behaviors, we examined the downstream target genes. The complementary of miR-34a-5p in the 3′-UTR of HOXA13 was obtained by using bioinformatics (Figure 3(a)). The miR-34a-5p mimic significantly reduced the luciferase activity of pmirGLO-HOXA13 wt in the SW982 cells but had nonsignificant effects on the pmirGLO-HOXA13 mut-transfected cells (Figure 3(b)). Additionally, the miR-34a-5p mimic significantly suppressed the mRNA and protein levels of HOXA13 in the SW982 cells (Figures 3(c) and 3(d)). Our study demonstrated that HOXA13 was the target of miR-34a-5p.

3.4. Apatinib Repressed the Malignant Behaviors of SW982 Cells via the miR-34a-5p/HOXA13 Axis. To determine the relationship between apatinib and the miR-34a-5p/HOXA13 axis in synovial sarcoma, both miR-34a-5p and HOXA13 were downregulated in SW982 cells. A decrease in the HOXA13 levels repressed the elevated proliferation in apatinib-treated SW982 cells in response to the miR-34a-5p inhibitor (Figure 4(a)). Silencing HOXA13 reduced clone formation in apatinib-treated SW982 cells in the presence of the miR-34a-5p inhibitor (Figure 4(b)). After apatinib increased cell apoptosis, treatment with the miR-34a-5p
Relative miR-34a-5p expression

(a) Control
Apatinib
Apatinib+NC inhibitor
Apatinib+miR-34a-5p inhibitor

(b) Control
Apatinib
Apatinib+NC inhibitor
Apatinib+miR-34a-5p inhibitor

(c) Control
Apatinib
Apatinib+NC inhibitor
Apatinib+miR-34a-5p inhibitor

Figure 2: Continued.
Figure 2: Continued.
inhibitor remarkably reduced cell apoptosis, which was reversed after the combined knockdown of miR-34a-5p and HOXA13 (Figure 4(c)). The miR-34a-5p inhibitor significantly promoted the migration and invasion of SW982 cells that was inhibited by apatinib, and this effect almost disappeared after a decrease in HOXA13 (Figures 4(d) and 4(e)). We determined the role of miR-34a-5p in VEGFR2, Ki67, cleaved caspase-3, and cleaved caspase-9. We found that HOXA13 knockdown in apatinib-treated SW982 cells significantly reversed the effect of the miR-34a-5p inhibitor on VEGFR2, Ki67, cleaved caspase-3, and cleaved caspase-9 (Figure 4(f)). Therefore, apatinib can regulate the miR-34a-5p/HOXA13 axis to inhibit malignant behaviors of SW982 cells.

### 3.5. Apatinib Emerged as a Tumor Suppressor of Synovial Sarcoma In Vivo.

To determine the effect of apatinib on synovial sarcoma in vivo, SW982 cells were subcutaneously inoculated into nude mice, and the mice were randomly divided into five groups: control, apatinib, apatinib+NC inhibitor, apatinib+miR-34a-5p inhibitor. The tumor volume and weight were monitored every week. The results showed that apatinib significantly inhibited the growth of SW982 tumors, and the combination treatment further reduced tumor growth (Figure 4(g)). We also found that apatinib significantly reduced the expression of VEGFR2, Ki67, cleaved caspase-3, and cleaved caspase-9 in SW982 cells (Figure 4(h)). Therefore, apatinib can be a potential therapeutic agent for synovial sarcoma.

---

**Figure 2:** Apatinib suppressed the SW982 cells by upregulating miR-34a-5p. The SW982 cells were stimulated with apatinib alone, apatinib along with the NC inhibitor, or apatinib and the miR-34a-5p inhibitor. (a) The expression of miR-34a-5p was determined by qPCR. (b, c) The proliferation of the cells was determined by CCK-8 and clone assays. (d) The apoptosis of the cells was evaluated by flow cytometry. (e) The migration of the cells was determined by wound healing. (f) The invasion of the cells was determined by the Transwell assay. (g) The protein levels of VEGFR2, Ki67, cleaved caspase-3, and cleaved caspase-9 in the SW982 cells were estimated by the western blot assay; *P < 0.05, **P < 0.01, and ***P < 0.001.
injected into BALB/c female mice, which were treated with 50 mg/kg apatinib for 30 d. Then, the tumor volume was measured every 5 d. The tumor volume decreased significantly after apatinib treatment compared to the tumor volume in the control group treated with DMSO (Figures 5(a) and 5(b)). VEGFR2 and Ki67 were used as the markers of angiogenesis and proliferation, respectively. From the results of immunohistochemistry, we found that apatinib reduced VEGFR2 and Ki67 and enhanced cleaved caspase-3 and cleaved caspase-9 in synovial sarcoma mice of the treatment group compared to their levels in the mice of the DMSO group (Figure 5(c)). According to the results of the western blot assay, cleaved caspase-3 and cleaved caspase-9 levels increased, and VEGFR2 and Ki67 levels decreased in apatinib-treated synovial sarcoma mice compared to their levels in the mice of the DMSO group (Figure 5(d)). We further examined the tumor tissues by performing qPCR and western blot analysis. The expression of miR-34a-5p was upregulated (Figure 5(e)) in the apatinib-treated synovial sarcoma mice, accompanied by a downregulation in the expression of HOXA13 (Figure 5(f)). Collectively, the results suggested that apatinib inhibited tumor growth in synovial sarcoma.

4. Discussion

We investigated the application of apatinib in synovial sarcoma treatment and determined its molecular regulation in tumorigenesis. In this study, a novel mechanism was elucidated, where apatinib played antiproliferative and proapoptotic roles in synovial sarcoma in vivo and in vitro via the miR-34a-5p/HOXA13 axis.

Apatinib can inhibit the tyrosine kinase activity of VEGFR2 in cells [31]. Previous studies showed that apatinib stimulated the inactivation of VEGFR2 to play antiproliferative and proapoptotic roles in ovarian cancer and colorectal cancer [32–34]. The mechanism of action of apatinib in synovial sarcoma remains unclear. A clinical report suggested that apatinib improved the prognosis of sarcoma patients in whom chemotherapy was ineffective [35]. In our study, the reduction of malignant behaviors and the enhancement of apoptosis in synovial sarcoma cancer cells in response to apatinib showed that apatinib can potentially inhibit the tumorigenesis of synovial sarcoma.

We also found that the administration of apatinib significantly enhanced miR-34a-5p in synovial sarcoma cells.
Figure 4: Continued.
miR-34a-5p plays an important role in cellular processes by regulating pathways associated with protein synthesis or tumorigenesis. Several studies have found that miR-34a-5p can regulate cellular processes in bone sarcoma. Two reports by Pu et al. [36, 37] suggested that mi-34a-5p developed osteosarcoma chemoresistance by targeting DLL1 and ATGR1, respectively. Silencing of miR-34a-5p by promoter methylation is associated with the detection of synovial sarcoma [23]. However, the function of miR-34a-5p in the tumorigenesis of synovial sarcoma remains unknown. In our study, an increase in the miR-34a-5p levels stimulated by apatinib attenuated proliferation, migration, and invasion of synovial sarcoma cells; also, it significantly increased apoptosis in these cells. These results indicated a novel drug-miRNA relationship where apatinib increases apoptosis and reduces the proliferation, invasion, and migration in synovial sarcoma cells by increasing the levels of miR-34a-5p.

We also found that HOXA13 might be the target of miR-34a-5p in cells. HOXA13 was repressed by miR-34a-5p in SW982 cells. Thus, we hypothesized that apatinib increases miR-34a-5p levels and, in turn, decreases HOXA13, leading to the inhibition of tumorigenesis and the progression of SW982 cells. The regulation of mRNA by miRNA significantly contributes to maintaining cellular processes. Empirical evidence suggests that HOXA13 expression can be
Figure 5: Apatinib emerged as a tumor suppressor of synovial sarcoma in vivo. The SW982 cells were subcutaneously injected into BALB/c female mice, which were treated with DMSO or 50 mg/kg apatinib for 30 d. (a) The image of the tumors from mice. (b) The statistical analysis of tumor volume. (c) The levels of VEGFR2, Ki-67, cleaved caspase-3, and cleaved caspase-9 were determined by immunohistochemistry. (d) The levels of VEGFR2, Ki-67, cleaved caspase-9, and cleaved caspase-3 were determined by the western blot assay; **P < 0.01 and ***P < 0.001.
regulated by miRNA at the posttranscriptional level. Liu et al. [38] showed that HOXA13 was the target of miR-381 and mediated the malignant behaviors of cervical cancer cells. Sun et al. [39] found that miR-185−5p targeted HOXA13 to increase cell survival in laryngeal squamous cell carcinoma. In our study, HOXA13 silencing reversed the antipatinib effect due to miR-34a-5p inhibition in synovial sarcoma cells, indicating that apatinib inhibited HOXA13 to repress tumorigenesis in synovial sarcoma cells via miR-34a-5p.

By elucidating the novel mechanism of action of apatinib, we showed its potential role in the diagnosis and prognosis of synovial sarcoma. The expression of miR-34a-5p and HOXA13 may be used as the biomarkers for the identification of synovial sarcoma and evaluation of cancer progression. Also, regulating the miR-34a-5p/HOXA13 axis might enhance the antitumorigenic effect of apatinib during synovial sarcoma treatment. VEGFR2-mediated angiogenesis effectively regulates nutrient supply and oxygen transport during tumorigenesis, leading to the enhancement of tumor metastasis and immune escape [40–42]. Our study showed that apatinib repressed the level of VEGFR2 in vivo, indicating that it had antiangiogenic effects on tumorigenesis in synovial sarcoma. However, we failed to understand its role in the angiogenesis of synovial sarcoma, which should be investigated in follow-up studies in vivo and in vitro.

In conclusion, we found that apatinib increased the levels of miR-34a-5p and repressed the expression of HOXA13, leading to a significant reduction in malignant behaviors and the enhancement of apoptosis in synovial sarcoma cells. Additionally, apatinib induced the inhibition of tumorigenesis in synovial sarcoma via the VEGFR2 pathway in vivo. Our study provided a mechanism of action of apatinib for the treatment of synovial sarcoma, suggesting a novel strategy for the management and diagnosis of the progression of synovial sarcoma.

**Abbreviations**

Annexin V-FITC: Annexin V-fluorescein isothiocyanate isomer  
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase  
U6: U6 small nuclear RNA  
qPCR: Quantitative real-time polymerase chain reaction  
VEGFR2: Vascular endothelial growth factor receptor 2  
CCK-8: Cell counting kit-8  
UTR: Untranslated region  
HOXA13: Homeobox A13  
STAT3: Signal transducer and activator of transcription 3  
Bcl-2: B-cell lymphoma-2  
Sox2: SRY-box transcription factor 2  
PD-L2: Programmed cell death 1 ligand 2  
Rhoa: Ras homolog family member A  
ROCK1: Rho-associated coiled-coil containing protein kinase 1  
LIMK2: LIM domain kinase 2  
miRNAs: MicroRNAs  
SD: Standard deviation  
DMSO: Dimethyl sulfoxide  
BCA: Bicinchoninic acid  
PVDF: Polyvinylidene difluoride  
ANOVA: Analysis of variance.

**Data Availability**

The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethical Approval**

This study was approved by the hospital ethics committee following the Health Guide of National Institutes for the Care and Use of Laboratory Animals (approval no. MDKN-2021-027).

**Conflicts of Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Authors’ Contributions**

This study was designed by Qi Feng and Jiangang Feng. Qi Feng and Donglai Wang conducted data curation and contributed to data collection and analysis. Donglai Wang, Peng Guo, and Zibo Zhang performed the experiments. Supervision was done by Jiangang Feng. Jiangang Feng revised it critically for important intellectual content. All authors approved the final version of the manuscript to be published.

**References**

[1] J. R. Popovich, S. Kashyap, and S. Cassaro, *Sarcoma*, StatPearls, Treasure Island (FL), 2021.

[2] J. Y. Hui, “Epidemiology and etiology of sarcomas,” *The Surgical Clinics of North America*, vol. 96, no. 5, pp. 901–914, 2016.

[3] A. Ferrari, U. Dirksen, and S. Bielack, “Sarcomas of soft tissue and bone,” *Tumors in Adolescents and Young Adults*, vol. 43, pp. 128–141, 2016.

[4] N. Pervaiz, N. Colterjohn, F. Farrokhyar, R. Tozer, A. Figueredo, and M. Ghert, “A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma,” *Cancer*, vol. 113, no. 3, pp. 573–581, 2008.

[5] J. H. Choi and J. Y. Ro, “The 2020 WHO classification of tumors of soft tissue: selected changes and new entities,” *Advances in Anatomic Pathology*, vol. 28, no. 1, pp. 44–58, 2021.

[6] I. Ray-Coquard, D. Serre, P. Reichardt, J. Martin-Broto, and S. Bauer, “Options for treating different soft tissue sarcoma subtypes,” *Future Oncology*, vol. 14, no. 10s, pp. 25–49, 2018.

[7] B. A. Nacev, K. B. Jones, A. M. Intlekofer et al., “The epigenomics of sarcoma,” *Nature Reviews Cancer*, vol. 20, no. 10, pp. 608–623, 2020.
A. Italiano, "Is there value in molecular profiling of soft-tissue sarcoma?,” Current Treatment Options in Oncology, vol. 19, no. 12, p. 78, 2018.

R. Geng and J. Li, "Apatinib for the treatment of gastric cancer," Expert Opinion on Pharmacotherapy, vol. 16, no. 1, pp. 117–122, 2015.

Z. R. Yang, Z. G. Chen, X. M. Du, and Y. Li, "Apatinib mesylate inhibits the proliferation and metastasis of epithelial malignant peritoneal mesothelioma in vitro and in vivo," Frontiers in Oncology, vol. 10, article 585079, 2020.

P. Fang, L. Zhang, X. Zhang et al., "Apatinib mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance - a multicenter randomized trial," Scientific Reports, vol. 9, no. 1, article 14013, 2019.

J. Zhao, H. Yu, T. Han, W. Wang, W. Tong, and X. Zhu, "A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer," Journal of BUON, vol. 24, no. 6, pp. 2267–2272, 2019.

Z. Tian, X. Wang, Z. Liu et al., "Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions," Cancer Management and Research, vol. 11, pp. 5293–5300, 2019.

K. Liu, T. Ren, Y. Huang et al., "Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma," Cell Death & Disease, vol. 8, no. 8, article e3015, 2017.

Z. C. Tian, J. Q. Wang, and H. Ge, "Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling," Journal of Orthopaedic Translation, vol. 22, pp. 132–141, 2020.

B. Zheng, C. Zhou, G. Qu et al., "VEGFR2 promotes metastasis and PD-L2 expression of human osteosarcoma cells by activating the STAT3 and RhoA-ROCK-LIMK2 pathways," Frontiers in Oncology, vol. 10, article 543562, 2020.

A. E. Sarver and S. Subramanian, "MicroRNAs in the pathobiology of sarcomas," Laboratory Investigation, vol. 95, no. 9, pp. 987–994, 2015.

R. Drury, E. T. Verghes, and T. A. Hughes, "The roles of microRNAs in sarcomas," The Journal of Pathology, vol. 227, no. 4, pp. 385–391, 2012.

L. Zhang, Y. Liao, and L. Tang, "MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer," Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, p. 53, 2019.

H. Welpner, I. Tsubulak, V. Wieser et al., "The miR-34 family and its clinical significance in ovarian cancer," Journal of Cancer, vol. 11, no. 6, pp. 1446–1456, 2020.

S. Xiong, M. Hu, C. Li, X. Zhou, and H. Chen, "Role of miR-34 in gastric cancer: from bench to bedside (review)," Oncology Reports, vol. 42, no. 5, pp. 1635–1646, 2019.

J. B. Krajewska, J. Fichna, and P. Mosinska, "One step ahead: miRNA-34 in colon cancer-future diagnostic and therapeutic tool?," Critical Reviews in Oncology/Hematology, vol. 132, pp. 1–8, 2018.

M. Vogt, J. Munding, M. Gruner et al., "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas," Virchows Archiv, vol. 458, no. 3, pp. 313–322, 2011.

D. F. Li, Y. Yuan, M. J. Tu et al., "The optimal outcome of suppressing Ewing sarcoma growth in vivo with bioengineered miR-34a-5p produrg," Frontiers in Oncology, vol. 10, p. 222, 2020.

M. Sciandra, A. De Feo, A. Parra et al., "Circulating miR-34a levels as a potential biomarker in the follow-up of Ewing sarcoma," Journal of Cell Communication and Signaling, vol. 14, no. 3, pp. 335–347, 2020.

M. T. Marino, A. Grilli, C. Baricordi et al., "Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression," Annals of Oncology, vol. 25, no. 10, pp. 2080–2086, 2014.

K. Nesteruk, V. T. Jamnaat, H. Liu, T. L. M. Ten Hagen, M. P. Peppelenbosch, and G. M. Fuhler, "Forced expression of HOXA13 confers oncogenic hallmarks to esophageal keratinocytes," Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1866, no. 8, article 165776, 2020.

L. Quagliata, C. Quintavalle, M. Lanzafame et al., "High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models," Laboratory Investigation, vol. 98, no. 1, pp. 95–105, 2018.

Y. X. He, X. H. Song, Z. Y. Zhao, and H. Zhao, "HOXA13 upregulation in gastric cancer is associated with enhanced cancer cell invasion and epithelial-to-mesenchymal transition," European Review for Medical and Pharmacological Sciences, vol. 21, no. 2, pp. 258–265, 2017.

S. Ji, S. Wang, X. Zhao, and L. Lv, "Long noncoding RNA NEAT1 regulates the development of osteosarcoma through sponging miR-34a-5p to mediate HOXA13 expression as a competitive endogenous RNA," Molecular Genetics & Genomic Medicine, vol. 7, no. 6, article e673, 2019.

L. J. Scott, "Apatinib: a review in advanced gastric cancer and other advanced cancers," Drugs, vol. 78, no. 7, pp. 747–758, 2018.

D. Chen, X. Cheng, W. Tu et al., "Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells," Cellular Oncology, vol. 42, no. 5, pp. 679–690, 2019.

X. Cai, B. Wei, L. Li et al., "Therapeutic potential of apatinib against colorectal cancer by inhibiting VEGFR2-mediated angiogenesis and β-catenin signaling," Oncotargets and Therapy, vol. 13, pp. 11031–11044, 2020.

S. Wen, G. Shao, J. Zheng, H. Zeng, J. Luo, and D. Gu, "Apatinib regulates the cells proliferation and apoptosis of liver cancer by regulation of VEGFR2/STAT3 signaling," Pathology, Research and Practice, vol. 215, no. 4, pp. 816–821, 2019.

F. Li, Z. Liao, J. Zhao et al., "Efficacy and safety of apatinib in stage IV sarcomas: experience of a major sarcoma center in China," Oncotarget, vol. 8, no. 38, pp. 64471–64480, 2017.

Y. Pu, F. Zhao, H. Wang, and S. Cai, "miR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLI1 gene," Scientific Reports, vol. 7, no. 1, article 44218, 2017.

C. Liu, X. Tian, J. Zhang, and L. Jiang, "Long non-coding RNA DLEU1 promotes proliferation and invasion by interacting
with miR-381 and enhancing HOXA13 expression in cervical cancer,” *Frontiers in Genetics*, vol. 9, p. 629, 2018.

[39] Y. D. Sun, Q. Liu, H. X. Yang et al., “Long non-coding RNA UCA1 mediates proliferation and metastasis of laryngeal squamous cell carcinoma cells via regulating miR-185-5p/HOXA13 axis,” *European Review for Medical and Pharmacological Sciences*, vol. 25, no. 3, pp. 1366–1378, 2021.

[40] L. Claesson-Welsh and M. Welsh, “VEGFA and tumour angiogenesis,” *Journal of Internal Medicine*, vol. 273, no. 2, pp. 114–127, 2013.

[41] T. H. Adair and J. P. Montani, *Angiogenesis*, Morgan & Claypool Life Sciences, San Rafael (CA), 2010.

[42] C. Viallard and B. Larrivee, “Tumor angiogenesis and vascular normalization: alternative therapeutic targets,” *Angiogenesis*, vol. 20, no. 4, pp. 409–426, 2017.